Scientific communications

M2 Macrophage Suppression Assay

03 / 13 / 2019

Our newly validated M2 suppression assay based on i) the co-culture of autologous monocyte-derived M2 macrophages and activated CD4+ T cells (or PBMCs) and on ii) the quantitation of IFNg levels as surrogate of T cell activation, is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages. 

Candidate compounds can thus be evaluated as single agents or in combinatorial treatments, for their potential to repolarize / switch M2 macrophages and to antagonize M2-mediated T cell suppression.

Intratumoral microdialysis-based approach to assess tumor immunometabolism & specific immunometabolic pathways-targeting

02 / 20 / 2019

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies. Nevertheless, the immunometabolic features of these tumors models, which may likely underlie responsiveness to immunotherapies, are still not well understood and become thus primordial to be defined for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.

New shuttle session with our in vivo syngeneic subcutaneous tumor models – for cost-saving efficacy studies

01 / 17 / 2019

Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models, over studies where a significant cost part will be supported by ourselves.

Neutrophil chemotaxis assay for cancer immunotherapy screening

12 / 06 / 2018

Besides their antimicrobial functions, neutrophils are likely infiltrating many types of tumors and increasing evidence correlate the tumor-associated neutrophils (TANs) with poor clinical outcome thereby supporting their role in tumor development. Recruitment of such TANs is indeed driven by key chemokines including the prototypical CXCL8 (IL8) or CXCL1 produced by tumor cells or its microenvironment. In turns, TANs might be involved in the recruitment of other immune cell populations (eg. Tregs, TAMs, etc), all together maintaining the local immunosuppressive microenvironment. Therefore acting on neutrophil recruitment and migration represents a valuable cancer immunotherapy strategy.

Start the New Year with an in vivo shuttle session on our syngeneic orthotopic glioblastoma mouse model

11 / 14 / 2018

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-January 2019, in which a cost part will be supported by Explicyte.

Mixed Lymphocyte Reaction for novel cancer immunotherapy testing

10 / 18 / 2018

The immunological synapse that occurs between T lymphocytes and Dendritic cells (DCs) is a key component of an effective immune response and is controlled by a combination of stimulatory and inhibitory signals – also called immune checkpoints. As to trigger a better anti-tumor immune response, interventions through a fine-tuning of these control signals within the immunological synapse represent one of the most promising cancer immunotherapy strategies.

Quantitative in vitro assays for pharmacological characterization of PD1/PDL1 and CTLA4 immune checkpoint blockade

09 / 19 / 2018

Activation of T cell immune response through regulation of immune checkpoint pathways is one of the most considerable strategies being employed in cancer immunotherapy, either as individual or in combination. While development of checkpoint inhibitors blocking PD1/PDL1 interaction is still a major interest thereby contributing to the suppression of tumor immune resistance, accurate identification and robust pharmacological characterization of modulatory agents thus become key and should be guaranteed through the assays.

New In Vivo Syngeneic Glioblastoma Mouse Model – Shuttle Session

05 / 23 / 2018

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-June, 2018. In this session, only experimental test groups-related costs will be covered by Sponsors ; control groups being supported by Explicyte.

New In Vivo Syngeneic Mammary Fat Pad Mouse Model Shuttle Session

02 / 28 / 2018

In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March.

In Vitro Immune Cell Activation

02 / 19 / 2018

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Upon activation, immune (T) cells undergo clonal expansion followed by differentiation into effectors to mediate cytotoxicity and/or cytokine release. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.